文献速递炎症性肠病

难治性克罗恩病双生物制剂联合治疗的有效性与安全性

Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease.
PubMed 文献 · Aliment Pharmacol Ther · 2020-04-24

该研究从两家转诊中心提取难治性克罗恩病患者双生物制剂治疗数据,评估其疗效与安全性。结果显示双生物制剂治疗与临床、生物标志物及内镜改善相关,13%的治疗试验出现不良事件,需进一步研究验证。

要点

  • 双生物制剂治疗在难治性克罗恩病中与内镜改善(43%)、临床缓解(41%)相关。
  • 治疗后中位SES-CD、PRO2及CRP均显著下降,肛周瘘管比例从50%降至33%。
  • 不良事件发生于13%的治疗试验,需进一步研究验证该方案。

核心结论

  • 双生物制剂治疗与经多种生物制剂治疗失败的难治性克罗恩病患者的临床、生物标志物及内镜改善相关。

研究设计与样本

  • 研究从两家转诊中心提取开始双生物制剂治疗的克罗恩病患者数据。
  • 共纳入22例患者,涉及24次双生物制剂治疗试验。
  • 使用的生物制剂包括英夫利西单抗、阿达木单抗、维得利珠单抗、乌司奴单抗、培塞利珠单抗和戈利木单抗。

主要发现

  • endoscopic improvement occurred in 43% of trials and 26% achieved endoscopic remission.
  • 50% had clinical response and 41% achieved clinical remission.
  • Median SES-CD decreased from 14.0 [12.0-17.5] to 6.0 [2.5-8.0], P = 0.0005.
  • Median PRO-2 decreased from 24.1 [20.3-27.0] to 13.4 [4.6-21.8], P = 0.002.
  • Median CRP decreased from 17.0 [11.0-24.0] to 9.0 [4.0-14.0], P = 0.02.

关键数值与推荐

  • 内镜改善定义为SES-CD较基线下降>50%或明确陈述。
  • 内镜缓解定义为SES-CD < 3或明确陈述。
  • 临床应答定义为PRO2评分降低8分。
  • 临床缓解定义为PRO2 < 8。

临床怎么用

  • 对于经多种生物制剂治疗失败的难治性克罗恩病患者,双生物制剂治疗可能作为避免反复手术的医疗选择。
  • 治疗期间需监测内镜、临床评分及CRP以评估应答。
  • 不良事件发生率13%,需关注安全性。

局限性

  • 样本量小(22例患者,24次治疗试验)。
  • 数据来自两家转诊中心,可能存在选择偏倚。
  • 需进一步研究验证该治疗方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Biologic therapies in patients with Crohn's disease often yield low clinical and endoscopic remission rates. After multiple failed therapies, combining two biologic therapies is possibly the sole medical alternative to recurrent surgery. However, data on this approach are limited. AIMS: To assess the efficacy and safety of concomitant use of two biologic therapies in the largest cohort to date of refractory Crohn's disease patients. METHODS: Data were extracted from Crohn's disease patients started on dual biologic therapy at two referral centres. Biologics utilised include infliximab, adalimumab, vedolizumab, ustekinumab, certolizumab and golimumab. The primary outcome was endoscopic improvement (>50% reduction in Simplified Endoscopic Score-Crohn's disease [SES-CD] or explicitly stated). Endoscopic remission (SES-CD < 3 or stated), clinical response (Crohn's disease-patient-reported outcome-2 score [PRO2] reduced by 8), clinical remission (PRO2 < 8), and C-reactive protein (CRP) were also assessed. RESULTS: A total of 22 patients with 24 therapeutic trials of dual biologic therapy were identified. The majority of patients had prior surgical resections (91%), stricturing (59%) or penetrating (36%) phenotype, and perianal fistulas (50%). Median number of prior failed biologics was 4. Endoscopic improvement occurred in 43% of trials and 26% achieved endoscopic remission. Fifty per cent had clinical response and 41% achieved clinical remission. There were significant post-treatment reductions in median SES-CD (14.0 [12.0-17.5] to 6.0 [2.5-8.0], P = 0.0005], PRO-2 (24.1 [20.3-27.0] to 13.4 [4.6-21.8], P = 0.002] and CRP (17.0 [11.0-24.0] to 9.0 [4.0-14.0], P = 0.02). Presence of perianal fistulas decreased from 50% to 33%. Adverse events occurred in 13% of trials. CONCLUSION: Dual biologic therapy was associated with clinical, biomarker and endoscopic improvements in selected patients with refractory Crohn's disease who failed multiple biologics. Further studies are needed to validate this approach.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Yang E, Panaccione N, Whitmire N, et al. Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease. Aliment Pharmacol Ther. 2020. PMID: 32329532. doi:10.1111/apt.15719

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。